These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16544440)

  • 1. Pegaptanib for neovascular age-related macular degeneration.
    Maberley D
    Issues Emerg Health Technol; 2005 Dec; (76):1-4. PubMed ID: 16544440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegaptanib: new drug. In macular degeneration: too many risks for too little benefit.
    Prescrire Int; 2006 Aug; 15(84):127-9. PubMed ID: 16989023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
    ; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
    Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N; Damico L; Shams N; Lowman H; Kim R
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
    Kourlas H; Schiller DS
    Clin Ther; 2006 Jan; 28(1):36-44. PubMed ID: 16490578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
    ; Chakravarthy U; Adamis AP; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Patel M
    Ophthalmology; 2006 Sep; 113(9):1508.e1-25. PubMed ID: 16828500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
    Takeda AL; Colquitt J; Clegg AJ; Jones J
    Br J Ophthalmol; 2007 Sep; 91(9):1177-82. PubMed ID: 17475698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegaptanib for neovascular age-related macular degeneration.
    Gragoudas ES; Adamis AP; Cunningham ET; Feinsod M; Guyer DR;
    N Engl J Med; 2004 Dec; 351(27):2805-16. PubMed ID: 15625332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegaptanib for the treatment of age-related macular degeneration.
    Zhou B; Wang B
    Exp Eye Res; 2006 Sep; 83(3):615-9. PubMed ID: 16678158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pegaptanib for wet macular degeneration.
    Fraunfelder FW
    Drugs Today (Barc); 2005 Nov; 41(11):703-9. PubMed ID: 16395411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranibizumab: new drug. Macular degeneration: second-line use due to risks.
    Prescrire Int; 2008 Feb; 17(93):3-6. PubMed ID: 18354841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
    Maier M; Feucht N; Huebner M; Lohmann C
    Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
    Nguyen QD; Shah SM; Hafiz G; Quinlan E; Sung J; Chu K; Cedarbaum JM; Campochiaro PA;
    Ophthalmology; 2006 Sep; 113(9):1522.e1-1522.e14. PubMed ID: 16876249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
    ; Apte RS; Modi M; Masonson H; Patel M; Whitfield L; Adamis AP
    Ophthalmology; 2007 Sep; 114(9):1702-12. PubMed ID: 17509689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New drugs; pegaptanib and ranibizumab].
    van Bronswijk H; Dubois EA; van Meurs JC; Cohen AF
    Ned Tijdschr Geneeskd; 2008 Jan; 152(2):82-4. PubMed ID: 18265796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory aspects of drug approval for macular degeneration.
    Gryziewicz L
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
    Sivaprasad S; Hykin P; Saeed A; Beatty S; Grisanti S; Staurenghi G; Olea JL; Campos A; Barbosa A; Rito L; Silva R; Faria R; Eldem B; Kadayifçilar S; Kolar P; Feucht N; Maestroni L
    Eye (Lond); 2010 May; 24(5):793-8. PubMed ID: 19786957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
    Atmani K; Coscas F; Coscas G; Soubrane G
    Eye (Lond); 2009 May; 23(5):1150-4. PubMed ID: 18636083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.